Article in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Typeobservational_patient_registrySponsorUniversity of PennsylvaniaRan2016 to 2027Enrolled1,000ConditionsCastleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 7 institutions in 1 country.
Mateo Sarmiento BustamanteCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0002-6774-2714
Saishravan ShyamsundarCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-0160-8910
Freda R CorenDepartment of Medical Education, Dell Medical School, Austin, Texas, USA.
Adam BaggDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gordan SrkalovicSparrow Herbert-Herman Cancer Center, Michigan State University College of Human Medicine, Lansing, Michigan, USA.
Daisy AlapatDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Frits van RheeMyeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0001-9959-1282
Megan S LimDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Mary Jo LechowiczDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA.
Joshua D BrandstadterDivision of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sheila K PiersonCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3736-1411
David C FajgenbaumCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-7367-8184
University of Pennsylvania · USDell Children's Medical Center of Central Texas · USEmory University · USMemorial Sloan Kettering Cancer Center · USSparrow Hospital · USUniversity of Arkansas for Medical Sciences · USWinthrop Rockefeller Foundation · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman DiseaseR01FD007632 · FDA · UNIVERSITY OF PENNSYLVANIA · PI Joshua D. Brandstadter, David C Fajgenbaum · 2022 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ongoing symptoms following complete surgical excision in unicentric Castleman disease. · full record | OpenQuestion